About

The Xgeva (denosumab) Dosing Calculator is designed to assist healthcare professionals by outlining the standard dosing regimens based on FDA-approved indications. It clarifies administration schedules, including loading doses, and provides critical safety alerts related to patient parameters like creatinine clearance and serum calcium.

Outputs

After processing the inputs, the calculator provides the following information:

• Recommended Dosing Regimen: The specific dose (120 mg) and administration frequency based on the selected indication.
• Loading Dose Schedule: For indications like Giant Cell Tumor of Bone (GCTB) and Hypercalcemia of Malignancy (HCM), it specifies the additional doses on Day 8 and Day 15 of the first month.
• Next Dose Date: If the last dose date is provided, the tool calculates the estimated due date for the next subcutaneous injection.
• Safety Alerts: The tool generates warnings for hypocalcemia (serum calcium <8.5 mg/dL) and cautions for patients with severe renal impairment (CrCl <30 mL/min).

How to use

To use the calculator, follow these steps:

1. Select Indication for Use: Choose the appropriate FDA-approved indication from the dropdown menu. This is a required field and determines the core dosing schedule.
2. Enter Creatinine Clearance (Optional): Input the patient's CrCl in mL/min to check for renal-related safety warnings.
3. Enter Serum Calcium (Optional): Input the patient's serum calcium in mg/dL to screen for pre-existing hypocalcemia, which must be corrected before starting therapy.
4. Enter Last Dose Date (Optional): Provide the date of the last Xgeva administration to calculate the next scheduled dose.

Dosing overview

The standard dose for all approved adult indications is 120 mg administered as a single subcutaneous (SC) injection.

• SRE Prevention (Solid Tumors & Multiple Myeloma): 120 mg SC every 4 weeks.
• Giant Cell Tumor of Bone (GCTB): 120 mg SC every 4 weeks, with additional 120 mg loading doses on Day 8 and Day 15 of the first month only.
• Hypercalcemia of Malignancy (HCM): 120 mg SC every 4 weeks, with additional 120 mg loading doses on Day 8 and Day 15 of the first month only.

Switching

Transitioning to Xgeva from another antiresorptive agent, such as an intravenous (IV) bisphosphonate (e.g., zoledronic acid), should be managed by a healthcare provider. A common approach is to administer the first 120 mg dose of Xgeva at the time the next scheduled dose of the IV bisphosphonate would have been due. No washout period is typically required, but clinical judgment should guide all treatment changes.

Missed dose

If a scheduled dose of Xgeva is missed, the patient should receive the injection as soon as it is reasonably possible. After the missed dose is administered, the dosing schedule should be re-established. The next injection should be scheduled 4 weeks from the date of the most recent injection to maintain the correct interval.

Safety alerts

Xgeva is associated with several important safety risks that require monitoring:

• Severe Hypocalcemia: Can occur, particularly in patients with severe renal impairment. Calcium levels must be corrected before starting Xgeva and monitored closely throughout treatment.
• Osteonecrosis of the Jaw (ONJ): Patients should have an oral examination and any necessary preventive dentistry completed before starting Xgeva. Maintaining good oral hygiene is critical.
• Atypical Femoral Fractures: Patients should be advised to report any new or unusual pain in the thigh, hip, or groin area.
• Hypercalcemia after Discontinuation (in GCTB): Clinically significant hypercalcemia can occur after stopping treatment, especially in patients with skeletal maturity. Monitor for signs and symptoms.

FAQ

1. What does the calculator show if I enter a serum calcium level below 8.5 mg/dL?
The tool will generate a "HYPOCALCEMIA WARNING," stating that pre-existing hypocalcemia must be corrected before initiating Xgeva therapy.

2. Does the calculator adjust the Xgeva dose for a patient with a CrCl below 30 mL/min?
No, the dose of Xgeva (120 mg) is not adjusted for renal impairment. However, the calculator will display a "RENAL IMPAIRMENT CAUTION" to highlight the increased risk of severe hypocalcemia in this population and the need for close monitoring.

3. What is the loading dose schedule for Giant Cell Tumor of Bone (GCTB)?
For GCTB, after the initial 120 mg dose on Day 1, additional 120 mg loading doses are given on Day 8 and Day 15 of the first month. Subsequent doses are given every 4 weeks.

4. How does the tool calculate the "next dose due date"?
It adds 28 days (4 weeks) to the "Last Dose Date" provided by the user to estimate the next administration date.

5. Is this calculator suitable for determining the dose for Prolia®?
No. Although Prolia also contains denosumab, it is formulated at a different strength (60 mg), used for different indications (e.g., osteoporosis), and has a different dosing schedule (every 6 months). This calculator is exclusively for Xgeva (120 mg).

6. What does "SRE" stand for in the indications?
SRE stands for Skeletal-Related Event. This includes pathologic fractures, radiation to bone, surgery to bone, or spinal cord compression.

7. Why is calcium and vitamin D supplementation so important with Xgeva?
Denosumab works by inhibiting osteoclast-mediated bone resorption, which can lead to a rapid decrease in serum calcium levels. Supplementation helps prevent treatment-induced hypocalcemia.

8. What is the difference in the dosing regimen for SRE prevention versus GCTB treatment?
Both indications use a maintenance dose of 120 mg SC every 4 weeks. However, the GCTB regimen includes two additional loading doses during the first month of therapy, whereas the SRE prevention regimen does not.

9. Can Xgeva be administered intravenously (IV)?
No. The calculator and prescribing information specify that Xgeva must only be administered via subcutaneous (SC) injection. It should not be given intravenously, intramuscularly, or intradermally.

References

1. XGEVA® (denosumab) Prescribing Information. Amgen Inc. U.S. Food and Drug Administration.
2. Xgeva (denosumab) Summary of Product Characteristics. European Medicines Agency.
3. XGEVA® for Healthcare Professionals. Amgen Oncology.
4. Denosumab. National Cancer Institute (NCI).